Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Portfolio Pulse from Avi Kapoor
Wall Street analysts have updated their price targets and ratings for several US-listed companies. Texas Instruments' target was raised by Keybanc, while Webster Financial and NuStar Energy saw increases from Raymond James and Stifel, respectively. Needham raised Apellis Pharmaceuticals' target, Citigroup upgraded Sunoco, and Canaccord Genuity increased Vertex Pharmaceuticals' target. Conversely, BMO Capital downgraded Plug Power, JP Morgan cut DXC Technology's target, Morgan Stanley downgraded Endava, and Keybanc raised Netflix's target. Most stocks mentioned closed lower on Tuesday, except for Apellis Pharmaceuticals and Netflix, which saw gains.
January 24, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham raised Apellis Pharmaceuticals' price target from $70 to $75 with a Buy rating. The stock rose 1.1% to close at $66.18.
The price target hike and Buy rating could contribute to continued positive momentum for Apellis Pharmaceuticals' stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Keybanc raised Netflix's price target from $545 to $580 and maintained an Overweight rating. The stock rose 1.3% to close at $492.19.
The increased price target and continued Overweight rating indicate strong analyst confidence, which may positively influence the stock's short-term trajectory.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Citigroup upgraded Sunoco from Neutral to Buy and raised the price target from $54 to $65. Shares fell 1.5% to close at $55.88.
The upgrade to Buy and increased price target suggest a positive short-term impact, which may lead to a rebound from the recent decline.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 75
POSITIVE IMPACT
Keybanc raised Texas Instruments' price target from $180 to $200 and maintained an Overweight rating. The stock fell 0.3% to close at $174.34.
The price target increase and Overweight rating by Keybanc could lead to a positive short-term sentiment, despite the recent slight decline in stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Raymond James increased Webster Financial's price target from $57 to $60 and maintained an Outperform rating. The stock fell 2.3% to close at $49.96.
The increased price target and Outperform rating indicate a positive outlook, which could counteract the recent drop and lead to short-term gains.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Morgan Stanley raised Endava's price target from $68 to $80 but downgraded the stock from Overweight to Equal-Weight. Shares fell 2.2% to close at $78.28.
The price target increase is positive, but the downgrade to Equal-Weight suggests a neutral stance, likely leading to short-term price stabilization.
CONFIDENCE 70
IMPORTANCE 55
RELEVANCE 65
NEUTRAL IMPACT
Stifel boosted NuStar Energy's price target from $20 to $23 but downgraded the stock from Buy to Hold. Shares fell 1.3% to close at $21.04.
The price target increase is positive, but the downgrade to Hold suggests a neutral short-term outlook, potentially stabilizing the stock price.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 60
NEGATIVE IMPACT
JP Morgan cut DXC Technology's price target from $27 to $24 and downgraded the stock from Neutral to Underweight. Shares fell 0.8% to close at $23.10.
The reduced price target and downgrade to Underweight could lead to further declines in the stock price in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
BMO Capital downgraded Plug Power from Market Perform to Underperform and cut the price target from $3.5 to $2.5. Shares gained 31% to close at $3.72.
The downgrade and reduced price target could negatively impact investor sentiment, potentially leading to a short-term price correction.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 85
NEGATIVE IMPACT
Canaccord Genuity raised Vertex Pharmaceuticals' price target from $332 to $379 but downgraded the stock from Hold to Sell. Shares fell 0.1% to close at $439.70.
The price target increase contrasts with the downgrade to Sell, which could create uncertainty and potentially lead to a short-term negative impact.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70